
Biotech makes a $303M run on Wall Street; Billionaire Thiel backs a startup round for antibiotic developer
⇨ It’s been another big week on the biotech IPO front. Deciphera $DCPH went public, raising $128 million for its solid tumor work, sticking to the top of the range at $17 a share. The UK’s Nightstar Therapeutics $NITE team — a gene therapy company — hit the middle of the range, raising $75 million at $14 a share. And NuCana, another UK biotech which jumped to Nasdaq, scored a cool $100 million from its IPO. NuCana says it is working on next-gen chemotherapies. Add it all up and you have a picture of a thriving biotech market, which is certain to attract more S-1s as the industry enjoys another upbeat run of new offerings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.